Effects of leflunomide (HWA 486) on expression of lymphocyte activation markers


Leflunomide (HWA 486), an isoxazol derivative, has been shown to be very effective in combating autoimmune diseases and transplantation rejection in a great number of animal models. The main metabolite of leflunomide, A77 1726, is a potent antiproliferative compound. To further elucidate this affect, lymphocytes of healthy human donors were cultured for 24… (More)
DOI: 10.1007/BF01991144


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.